Targeting the leukemia cell metabolism by the CPT1a inhibition: Functional preclinical effects in leukemias

Blood

Volumn 126, Issue 16, 2015, Pages 1925-1929

  Ricciardi, Maria Rosaria ^a   Mirabilii, Simone ^a   Allegretti, Matteo ^a   Licchetta, Roberto ^a   Calarco, Anna ^b   Torrisi, Maria Rosaria ^a   Foà, Robin ^a   Nicolai, Raffaella ^c   Peluso, Gianfranco ^b   Tafuri, Agostino ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CNR   (Italy)

^c Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE I; TEGLICAR; CARNITINE; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE 1A, HUMAN; FATTY ACID; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL METABOLISM; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME INHIBITION; FATTY ACID OXIDATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENZYMOLOGY; LEUKEMIA, MYELOID, ACUTE; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; TUMOR CELL LINE;

CARNITINE; CARNITINE O-PALMITOYLTRANSFERASE; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FATTY ACIDS; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM PROTEINS; OXIDATION-REDUCTION;

EID: 84944197809     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-12-617498     Document Type: Article

References (23)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011; 144(5): 646-674.
2. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011; 11(2): 85-95.
3. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008; 7(1): 11-20.
4. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009; 15(21): 6479-6483.
5. Robey RB, Hay N. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol. 2009; 19(1): 25-31.
6. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006; 3(3): 177-185.
7. Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem. 2008; 283(42): 28106-28114.
8. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009; 9(8): 563-575.
9. Jones RG, Plas DR, Kubek S, et al. AMPactivated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005; 18(3): 283-293.
10. Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: Fatty acid oxidation in the limelight. Nat Rev Cancer. 2013; 13(4): 227-232.
11. Paumen MB, Ishida Y, Han H, et al. Direct interaction of the mitochondrial membrane protein carnitine palmitoyltransferase I with Bcl-2. Biochem Biophys Res Commun. 1997; 231(3): 523-525.
12. Giordano A, Calvani M, Petillo O, et al. tBid induces alterations of mitochondrial fatty acid oxidation flux by malonyl-CoAindependent inhibition of carnitine palmitoyltransferase-1. Cell Death Differ. 2005; 12(6): 603-613.
13. Giannessi F, Pessotto P, Tassoni E, et al. Discovery of a long-chain carbamoyl aminocarnitine derivative, a reversible carnitine palmitoyltransferase inhibitor with antiketotic and antidiabetic activity. J Med Chem. 2003; 46(2): 303-309.
14. Anderson RC. Carnitine palmitoyltransferase: A viable target for the treatment of NIDDM? Curr Pharm Des. 1998; 4(1): 1-16.
15. Pacilli A, Calienni M, Margarucci S, et al. Carnitine-Acyltransferase system inhibition, cancer cell death, and prevention of myc-induced lymphomagenesis. J Natl Cancer Inst. 2013; 105(7): 489-498.
16. Ricciardi MR, Petrucci MT, Gregorj C, et al. Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia. Br J Haematol. 2001; 113(2): 391-399.
17. Tafuri A, Meyers J, Lee BJ, Andreeff M. DNA and RNA flow cytometric study in multiple myeloma. Clinical correlations. Cancer. 1991; 67(2): 449-454.
18. Jiffar T, Kurinna S, Suck G, et al. PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation. Leukemia. 2004; 18(3): 505-512.
19. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007; 7(10): 763-777.
20. Samudio I, Harmancey R, Fiegl M, et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest. 2010; 120(1): 142-156.
21. Tirado-Vélez JM, Joumady I, Sáez-Benito A, Cózar-Castellano I, Perdomo G. Inhibition of fatty acid metabolism reduces human myeloma cells proliferation. PLoS One. 2012; 7(9): E46484.
22. Caro P, Kishan AU, Norberg E, et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell. 2012; 22(4): 547-560.
23. Tung S, Shi Y, Wong K, et al. PPARa and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. Blood. 2013; 122(6): 969-980.